{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:30:54Z","timestamp":1784179854108,"version":"3.55.0"},"reference-count":42,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Henan Provincial Department of Education Key Scientific Research Project","award":["19A360006"],"award-info":[{"award-number":["19A360006"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,5,21]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Intravenous immunoglobulin (IVIg) is a first-line treatment for children with newly diagnosed immune thrombocytopenia (ITP). However, the cost of IVIg is high. Higher doses of IVIg are associated with a more insupportable financial burden to paediatric patients\u2019 families and may produce more adverse reactions. Whether low-dose IVIg can quickly stop bleeding and induce a durable response in treating children with newly diagnosed ITP is not yet established.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>We will extensively search five English databases (PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, Cumulative Index of Nursing and Allied Health Literature) and three Chinese databases (CNKI, Wanfang and VIP). International Clinical Trials Registry Platform and ClinicalTrials.gov will also be searched as supplementary. Randomised controlled trials and prospective observational studies compared the efficacy of low-dose IVIg and high-dose or moderate-dose IVIg will be included. The primary outcome is the proportion of patients achieving durable response. Estimates of effect will be pooled with either a random-effect model or a fixed-effect model according to the heterogeneity of studies. If significant heterogeneity exists, we will conduct subgroup analysis and sensitivity analysis to explore the source of heterogeneity and evaluate the robustness of the results. Publication bias will also be assessed, if possible. The risk of bias will be assessed using the Risk of Bias 2 and Risk Of Bias In Non-randomised Studies of Interventions tools. The certainty of evidence will be evaluated using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>No ethical approval is required since this systematic review is based on previously published studies. The findings of this study will be presented at international conferences or published in a peer-reviewed journal.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PROSPERO registration number<\/jats:title>\n                  <jats:p>CRD42022384604.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-071644","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T14:10:42Z","timestamp":1688047842000},"page":"e071644","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Low-dose intravenous immunoglobulin for children with newly diagnosed immune thrombocytopenia: protocol of a systematic review and meta-analysis"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5073-1528","authenticated-orcid":false,"given":"Xiangge","family":"Ren","sequence":"first","affiliation":[{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peidong","family":"Zhao","sequence":"additional","affiliation":[{"name":"College of Pediatrics, Henan University of Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Purpura and Nephropathy Center, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"2025101814184386000_13.6.e071644.1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"2025101814184386000_13.6.e071644.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044885","article-title":"Phase 3 randomised trial of Eltrombopag versus standard first-line pharmacological management for newly diagnosed immune Thrombocytopaenia (ITP) in children: study protocol","volume":"11","author":"Shimano","year":"2021","journal-title":"BMJ Open"},{"key":"2025101814184386000_13.6.e071644.3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune Thrombocytopenic purpura in children and adults: A critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"key":"2025101814184386000_13.6.e071644.4","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00277-021-04590-0","article-title":"Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia","volume":"100","author":"Grainger","year":"2021","journal-title":"Ann Hematol"},{"key":"2025101814184386000_13.6.e071644.5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fped.2017.00179","article-title":"The centenary of immune thrombocytopenia-part 2: revising diagnostic and therapeutic approach","volume":"5","author":"Consolini","year":"2017","journal-title":"Front Pediatr"},{"key":"2025101814184386000_13.6.e071644.6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"2025101814184386000_13.6.e071644.7","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1007\/s12325-021-01934-0","article-title":"Psychometric evaluation of ITP life quality index (ILQI) in a global survey of patients with immune thrombocytopenia","volume":"38","author":"Viana","year":"2021","journal-title":"Adv Ther"},{"key":"2025101814184386000_13.6.e071644.8","doi-asserted-by":"crossref","first-page":"100822","DOI":"10.1016\/j.blre.2021.100822","article-title":"Immune thrombocytopenia: A review of Upfront treatment strategies","volume":"49","author":"Kochhar","year":"2021","journal-title":"Blood Rev"},{"key":"2025101814184386000_13.6.e071644.9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0039-1684031","article-title":"First-line therapy for immune thrombocytopenia","volume":"39","author":"Mithoowani","year":"2019","journal-title":"Hamostaseologie"},{"key":"2025101814184386000_13.6.e071644.10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu429"},{"key":"2025101814184386000_13.6.e071644.11","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx039"},{"key":"2025101814184386000_13.6.e071644.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.04.032"},{"key":"2025101814184386000_13.6.e071644.13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-830844"},{"key":"2025101814184386000_13.6.e071644.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07275-6"},{"key":"2025101814184386000_13.6.e071644.15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/09537104.2016.1143923","article-title":"Hospitalizations in pediatric patients with immune thrombocytopenia in the United States","volume":"27","author":"Tarantino","year":"2016","journal-title":"Platelets"},{"key":"2025101814184386000_13.6.e071644.16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","journal-title":"Front Immunol"},{"key":"2025101814184386000_13.6.e071644.17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"key":"2025101814184386000_13.6.e071644.18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"2025101814184386000_13.6.e071644.19","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200310000-00011"},{"key":"2025101814184386000_13.6.e071644.20","first-page":"104","article-title":"Effect of different doses of intravenous Gammaglobulin combined with glucocorticoid in the treatment of children with idiopathic Thrombocytopenic purpura","volume":"38","author":"Ma","year":"2018","journal-title":"Clinical Medicine"},{"key":"2025101814184386000_13.6.e071644.21","first-page":"97","article-title":"Comparison of the therapeutic effects of different dose intravenous Gammaglobulin in treating children with idiopathic Thrombocytopenic purpura (ITP)","volume":"11","author":"Yang","year":"2018","journal-title":"Chinese J Clin Ration Drug Use"},{"key":"2025101814184386000_13.6.e071644.22","unstructured":"Wang J , Zhang M , Niu J . n.d. Clinical observation of the therapeutic effects of different dose intravenous Gammaglobulin in treating children with severe idiopathic Thrombocytopenic purpura (ITP). Chinese J Coal Industry Med;2003:80."},{"key":"2025101814184386000_13.6.e071644.23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","article-title":"The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic Thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials","volume":"21","author":"Qin","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2025101814184386000_13.6.e071644.24","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025101814184386000_13.6.e071644.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025101814184386000_13.6.e071644.26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances"},{"key":"2025101814184386000_13.6.e071644.27","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2352-3026(16)30109-0","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"key":"2025101814184386000_13.6.e071644.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.06.015"},{"key":"2025101814184386000_13.6.e071644.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.05.005"},{"key":"2025101814184386000_13.6.e071644.30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamapediatrics.2017.0057","article-title":"Comparison of antibiotic therapy and Appendectomy for acute uncomplicated Appendicitis in children: A meta-analysis","volume":"171","author":"Huang","year":"2017","journal-title":"JAMA Pediatr"},{"key":"2025101814184386000_13.6.e071644.31","article-title":"Transcranial direct current stimulation (tDCS) for improving Aphasia in adults with Aphasia after stroke","volume":"5","author":"Elsner","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101814184386000_13.6.e071644.32","doi-asserted-by":"crossref","DOI":"10.1186\/s13613-022-01091-9","article-title":"Sex and out-of-hospital cardiac arrest survival: a systematic review","volume":"12","author":"Lakbar","year":"2022","journal-title":"Ann Intensive Care"},{"key":"2025101814184386000_13.6.e071644.33","unstructured":"Page MS , Higgins J . On behalf of the development group for ROB-ME the ROB-ME (risk of bias due to missing evidence) tool: a new tool for assessing reporting biases in evidence syntheses. abstracts of the 25th Cochrane colloquium. Edinburgh. UK Cochrane Database of Systematic Reviews 2018."},{"key":"2025101814184386000_13.6.e071644.34","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062046","article-title":"Pcsk9 inhibitors for anti-inflammation in Atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Luo","year":"2022","journal-title":"BMJ Open"},{"key":"2025101814184386000_13.6.e071644.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-022-02146-5","article-title":"All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a protocol for a systematic review and meta-analysis","volume":"11","author":"Chornenki","year":"2022","journal-title":"Syst Rev"},{"key":"2025101814184386000_13.6.e071644.36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/biom.12817","article-title":"Quantifying publication bias in meta-analysis","volume":"74","author":"Lin","year":"2018","journal-title":"Biom"},{"key":"2025101814184386000_13.6.e071644.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2025101814184386000_13.6.e071644.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020400","article-title":"Acupuncture for constipation in patients with stroke: protocol of a systematic review and meta-analysis","volume":"8","author":"Zhai","year":"2018","journal-title":"BMJ Open"},{"key":"2025101814184386000_13.6.e071644.39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/imt.12.60","article-title":"30 years of Immunomodulation by intravenous immunoglobulin","volume":"4","author":"Imbach","year":"2012","journal-title":"Immunotherapy"},{"key":"2025101814184386000_13.6.e071644.40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10238-013-0255-4","article-title":"Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute","volume":"14","author":"Prabagar","year":"2014","journal-title":"Clin Exp Med"},{"key":"2025101814184386000_13.6.e071644.41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901872","article-title":"Systems biology and artificial intelligence analysis highlights the pleiotropic effect of Ivig therapy in autoimmune diseases with a predominant role on B cells and complement system","volume":"13","author":"Seg\u00fa-Verg\u00e9s","year":"2022","journal-title":"Front Immunol"},{"key":"2025101814184386000_13.6.e071644.42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.25086","article-title":"A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up","volume":"93","author":"Schifferli","year":"2018","journal-title":"Am J Hematol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-071644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:18:58Z","timestamp":1760822338000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-071644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,29]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjopen-2023-071644"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-071644","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}